Your session is about to expire
← Back to Search
Neuromodulation
TMS for Depression (TMS-LLD Trial)
N/A
Recruiting
Research Sponsored by University of New Mexico
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 3 post-treatment assessment
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to improve the effectiveness of a non-invasive brain stimulation technique for elderly patients with late-life depression by using imaging technology to precisely target brain areas involved in mood regulation. The goal is to provide a safer and more effective treatment option for those who have not responded well to traditional therapies. This brain stimulation technique has been studied for many years as a treatment for depression, showing potential benefits especially in older patients.
Who is the study for?
This trial is for English-speaking individuals aged 60-79 with major depressive disorder diagnosed by a psychiatrist, currently experiencing a depressive episode. Excluded are pregnant women, those with bipolar or psychotic disorders, recent hospitalization, neurosurgery history, ECT in the last three months, MRI contraindications, substance abuse within three months, seizure history or neurological disorders.
What is being tested?
The study tests how to improve transcranial magnetic stimulation (TMS), an existing treatment for late-life depression. It uses fMRI to personalize TMS targeting and assess its effectiveness in an open-label setting where all participants receive the intervention.
What are the potential side effects?
While not specified here, common side effects of rTMS may include headache or scalp discomfort at the site of stimulation. Rarely it can cause seizures or hearing loss if ear protection isn't used during treatment.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 3 post-treatment assessment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 3 post-treatment assessment
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Anterior Cingulate Cortex (ACC) Connectivity
Secondary study objectives
Depression Severity
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: rTMSExperimental Treatment1 Intervention
Subjects will receive rTMS to the area of the DLPFC most anticorrelated with the ACC.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
rTMS
2016
Completed Phase 3
~840
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Transcranial Magnetic Stimulation (TMS) is a non-invasive treatment for depression that uses magnetic fields to stimulate nerve cells in the brain, particularly targeting areas involved in mood regulation. Enhanced by functional MRI (fMRI), TMS can be more precisely targeted to the affected brain regions, potentially increasing its efficacy.
This matters for depression patients because it offers a treatment option that can be tailored to their specific neural activity patterns, potentially leading to better outcomes with fewer side effects compared to traditional pharmacotherapy. Understanding these mechanisms helps patients and clinicians make informed decisions about incorporating TMS into their treatment plans, especially for those who have not responded to conventional treatments.
[Historical review and recent research trends of the antidepressant repetitive transcranial magnetic stimulation (rTMS)].
[Historical review and recent research trends of the antidepressant repetitive transcranial magnetic stimulation (rTMS)].
Find a Location
Who is running the clinical trial?
The Mind Research NetworkOTHER
26 Previous Clinical Trials
2,318 Total Patients Enrolled
1 Trials studying Depression
62 Patients Enrolled for Depression
University of New MexicoLead Sponsor
388 Previous Clinical Trials
3,526,579 Total Patients Enrolled
16 Trials studying Depression
2,671 Patients Enrolled for Depression
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have had TMS treatment before.I have not had ECT treatment in the last 3 months.I have been diagnosed with a neurological or neurocognitive disorder.I have been diagnosed with major depression without psychosis by a psychiatrist.I am legally and mentally able to consent to the study.I have not been hospitalized nor had a severe illness in the last 3 weeks.I can attend all study visits and sessions on my own and on time.I have had seizures in the past.I have been diagnosed with a mental health condition like bipolar disorder or schizophrenia.I have had brain surgery before.I am between 60 and 79 years old.I have not used substances I'm addicted to in the last 3 months.
Research Study Groups:
This trial has the following groups:- Group 1: rTMS
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.